Polygenic Hyperlipidemias and Coronary Artery Disease Risk

Hyperlipidemia is a highly heritable risk factor for coronary artery disease (CAD). While monogenic familial hypercholesterolemia associates with severely increased CAD risk, it remains less clear to what extent a high polygenic load of a large number of LDL (low-density lipoprotein) cholesterol (LD...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation. Genomic and precision medicine Jg. 13; H. 2; S. e002725
Hauptverfasser: Ripatti, Pietari, Rämö, Joel T, Mars, Nina J, Fu, Yu, Lin, Jake, Söderlund, Sanni, Benner, Christian, Surakka, Ida, Kiiskinen, Tuomo, Havulinna, Aki S, Palta, Priit, Freimer, Nelson B, Widén, Elisabeth, Salomaa, Veikko, Tukiainen, Taru, Pirinen, Matti, Palotie, Aarno, Taskinen, Marja-Riitta, Ripatti, Samuli
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.04.2020
Schlagworte:
ISSN:2574-8300, 2574-8300
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Hyperlipidemia is a highly heritable risk factor for coronary artery disease (CAD). While monogenic familial hypercholesterolemia associates with severely increased CAD risk, it remains less clear to what extent a high polygenic load of a large number of LDL (low-density lipoprotein) cholesterol (LDL-C) or triglyceride (TG)-increasing variants associates with increased CAD risk. We derived polygenic risk scores (PRSs) with ≈6M variants separately for LDL-C and TG with weights from a UK Biobank-based genome-wide association study with ≈324K samples. We evaluated the impact of polygenic hypercholesterolemia and hypertriglyceridemia to lipid levels in 27 039 individuals from the National FINRISK Study (FINRISK) cohort and to CAD risk in 135 638 individuals (13 753 CAD cases) from the FinnGen project (FinnGen). In FINRISK, median LDL-C was 3.39 (95% CI, 3.38-3.40) mmol/L, and it ranged from 2.87 (95% CI, 2.82-2.94) to 3.78 (95% CI, 3.71-3.83) mmol/L between the lowest and highest 5% of the LDL-C PRS distribution. Median TG was 1.19 (95% CI, 1.18-1.20) mmol/L, ranging from 0.97 (95% CI, 0.94-1.00) to 1.55 (95% CI, 1.48-1.61) mmol/L with the TG PRS. In FinnGen, comparing the highest 5% of the PRS to the lowest 95%, CAD odds ratio was 1.36 (95% CI, 1.24-1.49) for the LDL-C PRS and 1.31 (95% CI, 1.19-1.43) for the TG PRS. These estimates were only slightly attenuated when adjusting for a CAD PRS (odds ratio, 1.26 [95% CI, 1.16-1.38] for LDL-C and 1.24 [95% CI, 1.13-1.36] for TG PRS). The CAD risk associated with a high polygenic load for lipid-increasing variants was proportional to their impact on lipid levels and partially overlapping with a CAD PRS. In contrast with a PRS for CAD, the lipid PRSs point to known and directly modifiable risk factors providing additional guidance for clinical translation.
AbstractList Hyperlipidemia is a highly heritable risk factor for coronary artery disease (CAD). While monogenic familial hypercholesterolemia associates with severely increased CAD risk, it remains less clear to what extent a high polygenic load of a large number of LDL (low-density lipoprotein) cholesterol (LDL-C) or triglyceride (TG)-increasing variants associates with increased CAD risk. We derived polygenic risk scores (PRSs) with ≈6M variants separately for LDL-C and TG with weights from a UK Biobank-based genome-wide association study with ≈324K samples. We evaluated the impact of polygenic hypercholesterolemia and hypertriglyceridemia to lipid levels in 27 039 individuals from the National FINRISK Study (FINRISK) cohort and to CAD risk in 135 638 individuals (13 753 CAD cases) from the FinnGen project (FinnGen). In FINRISK, median LDL-C was 3.39 (95% CI, 3.38-3.40) mmol/L, and it ranged from 2.87 (95% CI, 2.82-2.94) to 3.78 (95% CI, 3.71-3.83) mmol/L between the lowest and highest 5% of the LDL-C PRS distribution. Median TG was 1.19 (95% CI, 1.18-1.20) mmol/L, ranging from 0.97 (95% CI, 0.94-1.00) to 1.55 (95% CI, 1.48-1.61) mmol/L with the TG PRS. In FinnGen, comparing the highest 5% of the PRS to the lowest 95%, CAD odds ratio was 1.36 (95% CI, 1.24-1.49) for the LDL-C PRS and 1.31 (95% CI, 1.19-1.43) for the TG PRS. These estimates were only slightly attenuated when adjusting for a CAD PRS (odds ratio, 1.26 [95% CI, 1.16-1.38] for LDL-C and 1.24 [95% CI, 1.13-1.36] for TG PRS). The CAD risk associated with a high polygenic load for lipid-increasing variants was proportional to their impact on lipid levels and partially overlapping with a CAD PRS. In contrast with a PRS for CAD, the lipid PRSs point to known and directly modifiable risk factors providing additional guidance for clinical translation.
Hyperlipidemia is a highly heritable risk factor for coronary artery disease (CAD). While monogenic familial hypercholesterolemia associates with severely increased CAD risk, it remains less clear to what extent a high polygenic load of a large number of LDL (low-density lipoprotein) cholesterol (LDL-C) or triglyceride (TG)-increasing variants associates with increased CAD risk.BACKGROUNDHyperlipidemia is a highly heritable risk factor for coronary artery disease (CAD). While monogenic familial hypercholesterolemia associates with severely increased CAD risk, it remains less clear to what extent a high polygenic load of a large number of LDL (low-density lipoprotein) cholesterol (LDL-C) or triglyceride (TG)-increasing variants associates with increased CAD risk.We derived polygenic risk scores (PRSs) with ≈6M variants separately for LDL-C and TG with weights from a UK Biobank-based genome-wide association study with ≈324K samples. We evaluated the impact of polygenic hypercholesterolemia and hypertriglyceridemia to lipid levels in 27 039 individuals from the National FINRISK Study (FINRISK) cohort and to CAD risk in 135 638 individuals (13 753 CAD cases) from the FinnGen project (FinnGen).METHODSWe derived polygenic risk scores (PRSs) with ≈6M variants separately for LDL-C and TG with weights from a UK Biobank-based genome-wide association study with ≈324K samples. We evaluated the impact of polygenic hypercholesterolemia and hypertriglyceridemia to lipid levels in 27 039 individuals from the National FINRISK Study (FINRISK) cohort and to CAD risk in 135 638 individuals (13 753 CAD cases) from the FinnGen project (FinnGen).In FINRISK, median LDL-C was 3.39 (95% CI, 3.38-3.40) mmol/L, and it ranged from 2.87 (95% CI, 2.82-2.94) to 3.78 (95% CI, 3.71-3.83) mmol/L between the lowest and highest 5% of the LDL-C PRS distribution. Median TG was 1.19 (95% CI, 1.18-1.20) mmol/L, ranging from 0.97 (95% CI, 0.94-1.00) to 1.55 (95% CI, 1.48-1.61) mmol/L with the TG PRS. In FinnGen, comparing the highest 5% of the PRS to the lowest 95%, CAD odds ratio was 1.36 (95% CI, 1.24-1.49) for the LDL-C PRS and 1.31 (95% CI, 1.19-1.43) for the TG PRS. These estimates were only slightly attenuated when adjusting for a CAD PRS (odds ratio, 1.26 [95% CI, 1.16-1.38] for LDL-C and 1.24 [95% CI, 1.13-1.36] for TG PRS).RESULTSIn FINRISK, median LDL-C was 3.39 (95% CI, 3.38-3.40) mmol/L, and it ranged from 2.87 (95% CI, 2.82-2.94) to 3.78 (95% CI, 3.71-3.83) mmol/L between the lowest and highest 5% of the LDL-C PRS distribution. Median TG was 1.19 (95% CI, 1.18-1.20) mmol/L, ranging from 0.97 (95% CI, 0.94-1.00) to 1.55 (95% CI, 1.48-1.61) mmol/L with the TG PRS. In FinnGen, comparing the highest 5% of the PRS to the lowest 95%, CAD odds ratio was 1.36 (95% CI, 1.24-1.49) for the LDL-C PRS and 1.31 (95% CI, 1.19-1.43) for the TG PRS. These estimates were only slightly attenuated when adjusting for a CAD PRS (odds ratio, 1.26 [95% CI, 1.16-1.38] for LDL-C and 1.24 [95% CI, 1.13-1.36] for TG PRS).The CAD risk associated with a high polygenic load for lipid-increasing variants was proportional to their impact on lipid levels and partially overlapping with a CAD PRS. In contrast with a PRS for CAD, the lipid PRSs point to known and directly modifiable risk factors providing additional guidance for clinical translation.CONCLUSIONSThe CAD risk associated with a high polygenic load for lipid-increasing variants was proportional to their impact on lipid levels and partially overlapping with a CAD PRS. In contrast with a PRS for CAD, the lipid PRSs point to known and directly modifiable risk factors providing additional guidance for clinical translation.
Author Benner, Christian
Lin, Jake
Rämö, Joel T
Kiiskinen, Tuomo
Fu, Yu
Freimer, Nelson B
Pirinen, Matti
Ripatti, Pietari
Ripatti, Samuli
Palotie, Aarno
Söderlund, Sanni
Havulinna, Aki S
Palta, Priit
Widén, Elisabeth
Taskinen, Marja-Riitta
Mars, Nina J
Surakka, Ida
Tukiainen, Taru
Salomaa, Veikko
Author_xml – sequence: 1
  givenname: Pietari
  surname: Ripatti
  fullname: Ripatti, Pietari
  organization: Institute for Molecular Medicine Finland, Helsinki Institute of Life Science (HiLIFE) (P.R., J.T.R., N.J.M., Y.F., J.L., C.B., I.S., T.K., A.S.H., P.P., E.W., T.T., M.P., A.P., S.R.), University of Helsinki, Helsinki, Finland
– sequence: 2
  givenname: Joel T
  surname: Rämö
  fullname: Rämö, Joel T
  organization: Institute for Molecular Medicine Finland, Helsinki Institute of Life Science (HiLIFE) (P.R., J.T.R., N.J.M., Y.F., J.L., C.B., I.S., T.K., A.S.H., P.P., E.W., T.T., M.P., A.P., S.R.), University of Helsinki, Helsinki, Finland
– sequence: 3
  givenname: Nina J
  surname: Mars
  fullname: Mars, Nina J
  organization: Institute for Molecular Medicine Finland, Helsinki Institute of Life Science (HiLIFE) (P.R., J.T.R., N.J.M., Y.F., J.L., C.B., I.S., T.K., A.S.H., P.P., E.W., T.T., M.P., A.P., S.R.), University of Helsinki, Helsinki, Finland
– sequence: 4
  givenname: Yu
  surname: Fu
  fullname: Fu, Yu
  organization: Institute for Molecular Medicine Finland, Helsinki Institute of Life Science (HiLIFE) (P.R., J.T.R., N.J.M., Y.F., J.L., C.B., I.S., T.K., A.S.H., P.P., E.W., T.T., M.P., A.P., S.R.), University of Helsinki, Helsinki, Finland
– sequence: 5
  givenname: Jake
  surname: Lin
  fullname: Lin, Jake
  organization: Institute for Molecular Medicine Finland, Helsinki Institute of Life Science (HiLIFE) (P.R., J.T.R., N.J.M., Y.F., J.L., C.B., I.S., T.K., A.S.H., P.P., E.W., T.T., M.P., A.P., S.R.), University of Helsinki, Helsinki, Finland
– sequence: 6
  givenname: Sanni
  surname: Söderlund
  fullname: Söderlund, Sanni
  organization: Department of Internal Medicine, Helsinki University Hospital, Helsinki, Finland (S.S.)
– sequence: 7
  givenname: Christian
  surname: Benner
  fullname: Benner, Christian
  organization: Institute for Molecular Medicine Finland, Helsinki Institute of Life Science (HiLIFE) (P.R., J.T.R., N.J.M., Y.F., J.L., C.B., I.S., T.K., A.S.H., P.P., E.W., T.T., M.P., A.P., S.R.), University of Helsinki, Helsinki, Finland
– sequence: 8
  givenname: Ida
  surname: Surakka
  fullname: Surakka, Ida
  organization: Department of Internal Medicine, University of Michigan, Ann Arbor, MI (I.S.)
– sequence: 9
  givenname: Tuomo
  surname: Kiiskinen
  fullname: Kiiskinen, Tuomo
  organization: Institute for Molecular Medicine Finland, Helsinki Institute of Life Science (HiLIFE) (P.R., J.T.R., N.J.M., Y.F., J.L., C.B., I.S., T.K., A.S.H., P.P., E.W., T.T., M.P., A.P., S.R.), University of Helsinki, Helsinki, Finland
– sequence: 10
  givenname: Aki S
  surname: Havulinna
  fullname: Havulinna, Aki S
  organization: Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland (A.S.H., V.S.)
– sequence: 11
  givenname: Priit
  surname: Palta
  fullname: Palta, Priit
  organization: Institute for Molecular Medicine Finland, Helsinki Institute of Life Science (HiLIFE) (P.R., J.T.R., N.J.M., Y.F., J.L., C.B., I.S., T.K., A.S.H., P.P., E.W., T.T., M.P., A.P., S.R.), University of Helsinki, Helsinki, Finland
– sequence: 12
  givenname: Nelson B
  surname: Freimer
  fullname: Freimer, Nelson B
  organization: Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behaviour, University of California, Los Angeles, CA (N.B.F.)
– sequence: 13
  givenname: Elisabeth
  surname: Widén
  fullname: Widén, Elisabeth
  organization: Institute for Molecular Medicine Finland, Helsinki Institute of Life Science (HiLIFE) (P.R., J.T.R., N.J.M., Y.F., J.L., C.B., I.S., T.K., A.S.H., P.P., E.W., T.T., M.P., A.P., S.R.), University of Helsinki, Helsinki, Finland
– sequence: 14
  givenname: Veikko
  surname: Salomaa
  fullname: Salomaa, Veikko
  organization: Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland (A.S.H., V.S.)
– sequence: 15
  givenname: Taru
  surname: Tukiainen
  fullname: Tukiainen, Taru
  organization: Institute for Molecular Medicine Finland, Helsinki Institute of Life Science (HiLIFE) (P.R., J.T.R., N.J.M., Y.F., J.L., C.B., I.S., T.K., A.S.H., P.P., E.W., T.T., M.P., A.P., S.R.), University of Helsinki, Helsinki, Finland
– sequence: 16
  givenname: Matti
  surname: Pirinen
  fullname: Pirinen, Matti
  organization: Department of Mathematics and Statistics, Faculty of Science (M.P.), University of Helsinki, Helsinki, Finland
– sequence: 17
  givenname: Aarno
  surname: Palotie
  fullname: Palotie, Aarno
  organization: Department of Neurology (A.P.), Massachusetts General Hospital, Boston, MA
– sequence: 18
  givenname: Marja-Riitta
  surname: Taskinen
  fullname: Taskinen, Marja-Riitta
  organization: Clinical Research Institute HUCH, Ltd, Helsinki, Finland (M.-R.T.)
– sequence: 19
  givenname: Samuli
  surname: Ripatti
  fullname: Ripatti, Samuli
  organization: Broad Institute of MIT and Harvard, Cambridge, MA (S.R.)
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32154731$$D View this record in MEDLINE/PubMed
BookMark eNpNj01Lw0AQhhep2Fr7BzxIjl5SZ7-yWW8lrW2hqJTewyY7kdV8mW0O-fcGrODpmYHnHea9JZO6qZGQewpLSiP6lOyPyXbzOi56CcAUk1dkxqQSYcwBJv_mKVl4_wkAVGsdseiGTDmjUihOZ-T5vSmHD6xdHuyGFrvStc5i5YwPTG2DpOma2nRDsOrOOGLtPBqPwdH5rztyXZjS4-LCOTm9bE7JLjy8bffJ6hDmknIeagOZFhKsRBMVphDKZlER55bGhUIwNlNgdSYktVyNmhKi0CLWPIdcZZbNyePv2bZrvnv057RyPseyNDU2vU_ZmIojpgSM6sNF7bMKbdp2rhqfT__qsh-cxFnF
CitedBy_id crossref_primary_10_1016_j_jrras_2024_100930
crossref_primary_10_1016_j_crmeth_2022_100166
crossref_primary_10_1016_j_ajhg_2024_06_013
crossref_primary_10_1210_clinem_dgab876
crossref_primary_10_1038_s10038_021_00929_7
crossref_primary_10_1016_j_jrras_2024_100970
crossref_primary_10_1093_toxsci_kfac103
crossref_primary_10_1038_s41569_021_00638_w
crossref_primary_10_1038_s41591_022_02122_5
crossref_primary_10_1186_s12916_020_01762_z
crossref_primary_10_1186_s13073_021_00994_9
crossref_primary_10_1186_s12916_021_01977_8
crossref_primary_10_3390_biomedicines12040818
crossref_primary_10_1038_s43856_025_00981_w
crossref_primary_10_3390_v16071161
crossref_primary_10_1016_j_mmm_2021_12_007
crossref_primary_10_1097_MOL_0000000000000733
crossref_primary_10_1038_s41467_024_46102_4
crossref_primary_10_1161_ATVBAHA_120_315904
crossref_primary_10_1210_endocr_bqae146
crossref_primary_10_1016_j_msard_2021_103255
crossref_primary_10_1186_s12920_021_01127_2
crossref_primary_10_2217_bmm_2022_0797
crossref_primary_10_1097_MOL_0000000000000737
crossref_primary_10_3390_biomedicines12030617
crossref_primary_10_1186_s12920_023_01717_2
crossref_primary_10_3390_genes15050639
crossref_primary_10_1080_14779072_2025_2534707
crossref_primary_10_1038_s41467_021_26277_w
crossref_primary_10_3389_fcvm_2022_978998
crossref_primary_10_1177_00033197251350182
crossref_primary_10_1016_j_jacl_2020_11_006
crossref_primary_10_1161_CIRCRESAHA_123_323284
crossref_primary_10_15829_1560_4071_2024_5874
crossref_primary_10_1002_advs_202405955
crossref_primary_10_1007_s00335_023_10017_0
crossref_primary_10_1038_s41588_022_01221_w
crossref_primary_10_15829_1728_8800_2023_3846
crossref_primary_10_1186_s13073_021_00831_z
crossref_primary_10_1038_s41467_022_33510_7
crossref_primary_10_1038_s41598_025_13411_7
crossref_primary_10_1161_ATVBAHA_125_322801
crossref_primary_10_1371_journal_pgen_1011159
crossref_primary_10_1002_gepi_22392
crossref_primary_10_1210_endocr_bqaf100
crossref_primary_10_1089_met_2023_0125
crossref_primary_10_1093_humrep_deab086
crossref_primary_10_1097_MOL_0000000000000796
crossref_primary_10_3390_nu15204385
crossref_primary_10_1093_hmg_ddaa136
crossref_primary_10_1016_j_atherosclerosis_2023_117384
crossref_primary_10_1002_jbmr_4904
crossref_primary_10_1038_s41598_022_07465_0
crossref_primary_10_1161_ATVBAHA_123_320065
crossref_primary_10_1016_j_jhep_2022_04_010
crossref_primary_10_1097_HCO_0000000000000839
crossref_primary_10_3390_ijms22041593
crossref_primary_10_3390_genes15040462
crossref_primary_10_1016_j_tig_2021_08_009
crossref_primary_10_1093_genetics_iyaf018
ContentType Journal Article
CorporateAuthor FinnGen
CorporateAuthor_xml – name: FinnGen
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1161/CIRCGEN.119.002725
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 2574-8300
ExternalDocumentID 32154731
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: British Heart Foundation
  grantid: CH/1996001/9454
– fundername: Medical Research Council
  grantid: MC_PC_17228
– fundername: Medical Research Council
  grantid: MC_QA137853
GroupedDBID 53G
AAAAV
AAHPQ
AAIQE
AAJCS
AASCR
ABASU
ABDIG
ABJNI
ABPXF
ABVCZ
ABXYN
ABZZY
ACEWG
ACILI
ACXJB
ADGGA
ADHPY
AEBDS
AFBFQ
AFDTB
AFEXH
AFNMH
AHQNM
AHQVU
AHVBC
AINUH
AJCLO
AJIOK
AJNWD
AJZMW
AKCTQ
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
BQLVK
C45
CGR
CUY
CVF
DIWNM
EBS
ECM
EEVPB
EIF
EJD
FCALG
GNXGY
GQDEL
HLJTE
IKREB
IPNFZ
KQB
NPM
ODMTH
ODZKP
OHYEH
OPUJH
OVD
OVDNE
OXXIT
RAH
RIG
RLZ
TEORI
TSPGW
W2D
7X8
ADKSD
ID FETCH-LOGICAL-c5133-9a0b9450d5ea6faf47db6f8cd18f7e0adb70d9b451d3750d744f94893c0c7bd2
IEDL.DBID 7X8
ISICitedReferencesCount 71
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000529978000004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2574-8300
IngestDate Thu Oct 02 10:42:03 EDT 2025
Sat May 31 02:11:21 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords coronary artery disease
hypertriglyceridemia
risk factors
humans
hypercholesterolemia
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5133-9a0b9450d5ea6faf47db6f8cd18f7e0adb70d9b451d3750d744f94893c0c7bd2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ahajournals.org/doi/pdf/10.1161/CIRCGEN.119.002725
PMID 32154731
PQID 2375862740
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2375862740
pubmed_primary_32154731
PublicationCentury 2000
PublicationDate 2020-April-01
PublicationDateYYYYMMDD 2020-04-01
PublicationDate_xml – month: 04
  year: 2020
  text: 2020-April-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Circulation. Genomic and precision medicine
PublicationTitleAlternate Circ Genom Precis Med
PublicationYear 2020
SSID ssj0001999626
Score 2.4048295
Snippet Hyperlipidemia is a highly heritable risk factor for coronary artery disease (CAD). While monogenic familial hypercholesterolemia associates with severely...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage e002725
SubjectTerms Cholesterol, LDL - blood
Cohort Studies
Coronary Artery Disease - blood
Coronary Artery Disease - epidemiology
Coronary Artery Disease - etiology
Female
Genetic Predisposition to Disease
Genome-Wide Association Study
Humans
Hyperlipidemias - complications
Hyperlipidemias - genetics
Male
Middle Aged
Multifactorial Inheritance
Polymorphism, Single Nucleotide
Prognosis
Risk Factors
Triglycerides - blood
Title Polygenic Hyperlipidemias and Coronary Artery Disease Risk
URI https://www.ncbi.nlm.nih.gov/pubmed/32154731
https://www.proquest.com/docview/2375862740
Volume 13
WOSCitedRecordID wos000529978000004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFB7UinhxX-pGBK_BSWaSyXgRia0VbCilh97CZBYIlqQ2KvTf-yZJ6UkQvCTkkDC8fHn53jLvQ-iOcgNu3_iuVoK4VBLicqoVRK1MUUaEYaaeM_vGkiSaTvmoTbhVbVvlyifWjlqV0ubI730CzNYKxeDH-YdrVaNsdbWV0NhEHQJUxrZ0sWm0zrFYNl8rrgEwqRsRjFf7ZkLvPn4dxy-9BC7syEqf-cHvLLP-2_T3_7vOA7TX8kznqQHGIdrQxRHaGbaV9GP0MCpnSwBPLp0BhKKLWd5IxYrKEYVyYjvYQCyW9gEaTs9NHccZ59X7CZr0e5N44LY6Cq606i0uFzjjNMAq0CI0wlBm995FUnmRYRoLlTGseEYDT8HisWKUGm6H0kgsWab8U7RVlIU-R06kwIQ6CjmQCup7RnBNPSqEVoR4Mgi76HZllBRgamsPotDlV5WuzdJFZ41l03kzTyMlQDsAF97FH-6-RLu-jXjr3pkr1DHwkeprtC2_P_NqcVO_fzgmo-EPLcu4jA
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Polygenic+Hyperlipidemias+and+Coronary+Artery+Disease+Risk&rft.jtitle=Circulation.+Genomic+and+precision+medicine&rft.au=Ripatti%2C+Pietari&rft.au=R%C3%A4m%C3%B6%2C+Joel+T&rft.au=Mars%2C+Nina+J&rft.au=Fu%2C+Yu&rft.date=2020-04-01&rft.eissn=2574-8300&rft.volume=13&rft.issue=2&rft.spage=e002725&rft_id=info:doi/10.1161%2FCIRCGEN.119.002725&rft_id=info%3Apmid%2F32154731&rft_id=info%3Apmid%2F32154731&rft.externalDocID=32154731
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2574-8300&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2574-8300&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2574-8300&client=summon